Nkarta (NASDAQ:NKTX) President Nadir Mahmood Sells 5,649 Shares of Stock

Nkarta, Inc. (NASDAQ:NKTX) President Nadir Mahmood sold 5,649 shares of the company’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $2.07, for a total transaction of $11,693.43. Following the sale, the president directly owned 167,727 shares in the company, valued at $347,194.89. This trade represents a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Nkarta Price Performance

Shares of NKTX opened at $2.04 on Wednesday. The company has a market cap of $144.90 million, a PE ratio of -1.48 and a beta of 0.60. The firm has a 50-day moving average of $1.88 and a 200-day moving average of $2.03. Nkarta, Inc. has a one year low of $1.31 and a one year high of $2.74.

Nkarta (NASDAQ:NKTX) last issued its earnings results on Monday, November 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.03. Analysts expect that Nkarta, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Nkarta in a report on Monday, December 29th. Wall Street Zen raised shares of Nkarta from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Finally, Stifel Nicolaus decreased their price objective on shares of Nkarta from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, November 11th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $13.25.

Hedge Funds Weigh In On Nkarta

Institutional investors and hedge funds have recently modified their holdings of the business. Invesco Ltd. increased its position in Nkarta by 478.4% during the first quarter. Invesco Ltd. now owns 69,396 shares of the company’s stock worth $128,000 after acquiring an additional 57,399 shares during the period. AQR Capital Management LLC grew its position in shares of Nkarta by 300.5% during the 1st quarter. AQR Capital Management LLC now owns 672,078 shares of the company’s stock worth $1,237,000 after purchasing an additional 504,272 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Nkarta by 13.3% during the first quarter. Goldman Sachs Group Inc. now owns 681,068 shares of the company’s stock worth $1,253,000 after purchasing an additional 80,211 shares during the period. Jane Street Group LLC increased its holdings in shares of Nkarta by 118.7% during the first quarter. Jane Street Group LLC now owns 134,286 shares of the company’s stock worth $247,000 after purchasing an additional 852,559 shares during the period. Finally, CWM LLC raised its position in shares of Nkarta by 23.4% in the second quarter. CWM LLC now owns 34,758 shares of the company’s stock valued at $58,000 after buying an additional 6,601 shares in the last quarter. 80.54% of the stock is currently owned by institutional investors and hedge funds.

About Nkarta

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.